ITOS ITeos Therapeutics
- 18.090
- +0.040+0.22%
ITeos Therapeutics News
ITeos Therapeutics (NASDAQ:ITOS): Harnessing the Power of Immunotherapy
Merck Discontinues Testing of Experimental Skin Cancer Combo Therapy
ITeos Therapeutics Is Maintained at Buy by HC Wainwright & Co.
ITeos Therapeutics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : The iTeos Therapeutics (ITOS.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $44.00 to $46.00.
HC Wainwright & Co. : The iTeos Therapeutics (ITOS.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $44.00 to $46.00.
HC Wainwright & Co. Maintains Buy on ITeos Therapeutics, Raises Price Target to $46
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains ITeos Therapeutics with a Buy and raises the price target from $44 to $46.
ITeos Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 156.98% HC Wainwright & Co. $44 → $46 Maintains Buy 03/12/2024 50.84% JP Morgan $29 → $27 Maint
ITeos Therapeutics Shares Surge 47% After Promising Tumor Treatment Data
By Ben Glickman Shares of iTeos Therapeutics rose sharply after the company said one of its tumor treatment clinical trials had shown promising interim results. The stock was up 47% to $17.86 in Fri
Riding High: ITeos Therapeutics' (ITOS) Stock Surges Amid Market Activity
Following the dissemination of a corporate update and financial appraisal, the stock of iTeos Therapeutics, Inc. (NASDAQ: ITOS) has experienced a surge in value during the present trading session. At the latest market evaluation, ITOS shares demonstrated an increase of 46.31% on the US stock exchanges, reaching $17.83. Clinical Advancements: Promising Developments In GALAXIES Lung-201 ...
ITeos Therapeutics Up Over 46%, On Track for Record Percent Increase -- Data Talk
iTeos Therapeutics, Inc. (ITOS) is currently at $17.81, up $5.62 or 46.1% --Would be highest close since May 26, 2023, when it closed at $18.05 --Would be largest percent increase on record (Based o
NVAX, GRPN and MVIS Among Mid-day Movers
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Diodes posted adjusted earnings of 28 cents
Wedbush Adjusts ITeos Therapeutics' Price Target to $21 From $18, Maintains Outperform Rating
iTeos Therapeutics (ITOS) has an average rating of outperform and price targets ranging from $18 to $47, according to analysts polled by Capital IQ. Price: 17.77, Change: +5.58, Percent Change: +45.73
Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday
U.S. stocks were mostly higher, with the Dow Jones gaining over 100 points on Friday.
Novavax, Macrogenics, Biofrontera Among Healthcare Movers
ITeos Therapeutics Reports Q1 Results
Market-Moving News for May 10th
ITOS: 39% | iTeos Therapeutics shares are trading higher after the company announced a $120 million registered direct offering and reported Q1 financial results.NVAX: 100% | Novavax shares are trading
ITeos Therapeutics | 10-Q: Quarterly report
ITeos Therapeutics Expects Topline Data From Phase 1 Trial In 2H 2024
ITeos Therapeutics Expects Topline Data From Phase 1 Trial In 2H 2024
ITeos Therapeutics 1Q Loss $38.2M >ITOS
ITeos Therapeutics 1Q Loss $38.2M >ITOS
ITeos Therapeutics Q1 2024 GAAP EPS $(1.07) Misses $(1.02) Estimate
ITeos Therapeutics (NASDAQ:ITOS) reported quarterly losses of $(1.07) per share which missed the analyst consensus estimate of $(1.02) by 4.9 percent.
Analysis
Price Target
No Data
